Development and Pre-Clinical Evaluation of Two LAIV Strains against Potentially Pandemic H2N2 Influenza Virus

• Irina Isakova-Sivak ,

  Contributed equally to this work with: Irina Isakova-Sivak, Jørgen de Jonge

  Affiliation Institute for Experimental Medicine, Saint Petersburg, Russia

  ⨯
• Jørgen de Jonge ,

  Contributed equally to this work with: Irina Isakova-Sivak, Jørgen de Jonge

  * E-mail: jorgen.de.jonge@rivm.nl

  Affiliation Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands

  ⨯
• Tatiana Smolonogina,

  Affiliation Institute for Experimental Medicine, Saint Petersburg, Russia

  ⨯
• Andrey Rekstin,

  Affiliation Institute for Experimental Medicine, Saint Petersburg, Russia

  ⨯
• Geert van Amerongen,

  Affiliation Animal Research Center, InTraVacc, Bilthoven, the Netherlands

  ⨯
• Harry van Dijken,

  Affiliation Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands

  ⨯
• Justin Mouthaan,

  Affiliation Centre for Infectious Disease Control, RIVM, Bilthoven, the Netherlands

  ⨯
• Paul Roholl,

  Affiliation Microscope Consultancy, Weesp, the Netherlands

  ⨯
• Victoria Kuznetsova,

  Affiliation Institute for Experimental Medicine, Saint Petersburg, Russia

  ⨯
• Elena Doroshenko,

  Affiliation Institute for Experimental Medicine, Saint Petersburg, Russia

  ⨯
• Vadim Tsvetnitsky,

  Affiliation PATH Vaccine Development Global Program, Seattle, Washington, United States of America

  ⨯
• Larisa Rudenko

  Affiliation Institute for Experimental Medicine, Saint Petersburg, Russia

  ⨯